Rating Change: H.C. Wainwright Maintains $18 PT On Akebia Therapeutics (NASDAQ:AKBA), Maintains Buy Rating - Thorold News

Thorold News
Rating Change: H.C. Wainwright Maintains $18 PT On Akebia Therapeutics (NASDAQ:AKBA), Maintains Buy Rating
Thorold News
Akebia Therapeutics (NASDAQ:AKBA) had its stock rating noted as Buy by analysts at H.C. Wainwright. H.C. Wainwright currently has a $18 target price per share on the $426.77M market cap company or 69.81% upside potential. This was disclosed in a note ...
Akebia Therapeutics (AKBA): Phase III Funding In The Bag - HC Wainwright; PT up to $18StreetInsider.com
Ak